Vinva Investment Management Ltd Increases Holdings in Amgen Inc.

Firm boosts stake in biotech giant by over 21% in Q3

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Vinva Investment Management Ltd, a global investment management firm, increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 21.5% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 44,908 shares of the medical research company's stock, valued at $12.3 million.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a focus on developing innovative human therapeutics to address serious illnesses. As a major institutional investor, Vinva's increased stake in Amgen signals confidence in the company's long-term growth prospects and pipeline of drug candidates.

The details

According to the 13F filing, Vinva Investment Management purchased an additional 7,958 shares of Amgen during the third quarter, bringing its total position to 44,908 shares. This represents a 21.5% increase in the firm's holdings of the medical research company's stock. Amgen's shares have seen strong performance in recent quarters, driven by the success of its key drug products and a robust research and development pipeline.

Vinva Investment Management increased its Amgen holdings during the third quarter of 2026.

The players